Johnson & Johnson's Spravato therapy for treatment-resistant depression (TRD) hasn't made the impact the company hoped for in the market, and it is looking to new clinical results to accelerate ...

A private equity group has agreed to take over most of IBM Watson Health, seven years after the business was launched with a pledge to revolutionise healthcare data analysis. Francisco Partners is ...

GSK's vaccine against respiratory syncytial virus (RSV) is one of the top prospects in its pipeline, but also one with considerable competition, so needs strong data to support the programme ...

A recent healthcare report conducted by Edelman reveals a concerning trend of declining public trust in healthcare institutions. Explore the key findings and implications in this comprehensive ...

Purdue Pharma and its controlling Sackler family have offered a new settlement to resolve lawsuits over their involvement in the opioid epidemic, raising the payout from the Sacklers to $6 billion ...

After more than six years of development, Angle has scored an FDA approval for Parsortix as a diagnostic for metastatic breast cancer – the first ever in the US for a device used to detect ...

Paul Stoffels' retirement at the end of last year after nine years as head of R&D at Johnson & Johnson was short lived – he's just been named chef executive of Galapagos. Stoffels will take the ...

GSK has teamed up with two research organisations in the UK to explore a possible link between its shingles vaccine, Shingrix, and a reduced risk of dementia. The tantalising hypothesis – drawn ...

Bristol-Myers Squibb’s KRAS inhibitor Krazati has been approved for a second indication, colorectal cancer (CRC), which could inject some much-needed sales growth into the product. The FDA has ...

A personalised cell therapy based on tumour-infiltrating lymphocyte (TIL) cells has been shown to be more effective at improving progression-free survival than Bristol-Myers Squibb's immunotherapy ...

Novartis chief executive Vas Narasimhan, already eyeing a possible divestment of generics business Sandoz, has now turned his attention to the rest of the company.

Armed with new phase 3 data, Bayer has started preparing filings for elinzanetant as a treatment for vasomotor symptoms (VMS) associated with menopause, setting up a challenge to Astellas’ first ...